Publications by authors named "Rupesh Subash"

Claim this Profile
D
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany.
Rupesh Subash, Cecilia Duan, Anshul Shah, Dionne M Hines, Michelle Zhang

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of all-cause health care resource utilization and costs among patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding in France: a nationwide cohort analysis.
Giancarlo Pesce, Gaelle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Rupesh Subash

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of drug utilization management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving DOACs in the US.
Rupesh Subash, Elisabeth Vodicka, Serina Deeba, Chloe Salter, Carissa Dickerson

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the direct oral anticoagulant switch study: effect of switching or continuing apixaban or rivaroxaban among people with non-valvular atrial fibrillation.
Steven Deitelzweig, Jenny Jiang, Rupesh Subash, Dong Cheng, Gregory Y H Lip

Future Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative safety and effectiveness of direct oral anticoagulants and warfarin in patients with venous thromboembolism in Finland, Norway and Sweden.
Waleed Ghanima, Hanna Pohjantähti, Dimitra Lambrelli, Beth Nordstrom, Alison Booth, Rupesh Subash

J Comp Eff Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting.
Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek

J Comp Eff Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total.
Nipun Atreja, Kasper Johannesen, Rupesh Subash, Carina Bektur, Melissa Hagan

J Comp Eff Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS).
Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Rupesh Subash

PLoS One· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study.
Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Rupesh Subash

PLoS One· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis